Nanodisc Founder Dr. Stephen Sligar to Chair BIO 2004 Panel Presentation On Significant Advances in Targeting Membrane Proteins

Jun 07, 2004, 01:00 ET from Nanodisc, Inc.

    SAN FRANCISCO, June 7 /PRNewswire/ -- Nanodisc, Inc., a nano-bio
 convergence company commercializing nanotechnologies for drug discovery and
 delivery, announced that today at the BIO 2004 Annual International
 Convention, Stephen Sligar, Ph.D., Nanodisc co-founder/chief scientific
 officer and professor at the University of Illinois, will chair a panel
 discussion focused on recent advancements that are enabling more effective
 drug discovery efforts against membrane-bound protein targets.  Dr. Sligar
 will be joined by speakers including James Wells of Sunesis Pharmaceuticals;
 Brian Hubbard of the Novartis Institutes for BioMedical Research; and Barry
 Springer of 3-Dimensional Pharmaceuticals.
     Compounds addressing membrane-bound targets constitute the majority of
 pharmaceutical products marketed today.  However, these targets are
 notoriously difficult and expensive to study using traditional tools of drug
 discovery because they lose their natural characteristics when removed from
 their native environments, but cannot be easily manipulated and studied in
 those environments.  To address this challenge, Dr. Sligar developed
 Nanodisc(TM) technology, a nano-scale, self-assembling disc that incorporates
 target molecules such as membrane proteins in such a way that their natural
 structural and functional characteristics are preserved and can be directly
 investigated.  Nanodisc technology is an important, less expensive enabler for
 many molecular discovery approaches practiced by large life sciences
 companies, and represents an important advance in drug formulation and
     Dr. Sligar's panel, entitled "Membrane Proteins as Targets," will take
 place Monday, June 7, at 11:00 AM (pacific time) in room 2018 West at the
 Moscone Center in San Francisco.  The BIO 2004 Annual International Convention
 is being held June 6-9.
     About Nanodisc
     Nanodisc Inc. commercializes Nanodisc(TM) technology to enable more
 effective and less expensive discovery of new drugs against membrane protein
 targets, the largest class of drug targets, and for drug delivery and drug
 formulation.  Founded by Stephen Sligar, Ph.D., professor at the University of
 Illinois, Nanodisc has a worldwide, exclusive commercial license for all
 applications of Nanodisc technology with the U of I.  For more information,
 please visit .
     For further information please contact:  Carin Canale of
 Atkins + Associates, +1-858-336-3027, for Nanodisc, Inc.

SOURCE Nanodisc, Inc.